secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0000950170-24-036151
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss
--------------------------------------------------------------------------------

- Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735
- Placebo-adjusted mean weight loss up to 3.3%; up to 57% of treated subjects achieved ≥5% weight loss vs 0% placebo
- VK2735 well-tolerated with low GI adverse events; no serious adverse events reported
- Company plans Phase 2 trial in obesity for second half of 2024

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/0000950170-24-036151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024036151/vktx-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer